New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 13, 1998, Pages 2514-2516

  Clark, Abbot F ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; AQUEOUS HUMOR OUTFLOW; EXTRACELLULAR MATRIX; GLAUCOMA; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; PROTEIN FAMILY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TRABECULOPLASTY;

ANIMALS; BIOLOGY; EYE DISEASES; HUMANS; METALLOENDOPEPTIDASES; OCULAR PHYSIOLOGY;

EID: 0031768663     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Woessner JF. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego: Academic Press; 1998:1-14.
2. Lutjen-Drecoll E, Rohen JW. Morphology of aqueous outflow pathways in normal and glaucomatous eyes. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St. Louis: Mosby; 1996:89-123.
3. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32:172-180.
4. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993; 34:3386-3395.
5. Alexander JP, Samples JR, Acott TS. Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr Eye Res. 1998;17:276-285.
6. Snyder RW, Stamer WD, Kramer TR, Seftor REB. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res. 1993;57:461-468.
7. Johnson D, Gottanka J, Flugel C, Hoffman F, Futa R, Lutjen-Drecoll E. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol. 1997;115: 375-383.
8. Bradley JMB, Vranka J, Colvis CM, et al. Manipulation of matrix metalloproteinases activity modulates outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
9. Parshley DE, Bradley JMB, Samples JR, Van Buskirk EM, Acott TS. Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Curr Eye Res. 1995;14:537-544.
10. Parshley DE, Bradley JMB, Fisk A, et al. Laser trabeculoplasty induces stromelysin expression by trabecular juxtacanalicular cells. Invest Ophthalmol Vis Sci. 1996;37:795-804.
11. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389-402.
12. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997; 38:2772-2780.
13. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179-191.
14. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38:2214-2223.
15. 2a in iris root, ciliary muscle and adjacent sclera of monkey eyes (ARVO Abstract). Invest Ophthalmol Vis Sci. 1998;39:S929. Abstract nr 4276.
16. Weber BHF, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet. 1994;8:352-356.
17. Vranka JA, Johnson E, Zhu X, et al. Discrete expression and distribution pattern of TIMP-3 in the human retinal and choroid. Curr Eye Res. 1997;16:102-110.
18. Felbor U, Doepner D, Schneider U, Zrenner E, Weber BH. Evaluation of the gene encoding the tissue inhibitor of metalloprotein-ases-3 in various maculopathies. Invest Ophthalmol Vis Sci. 1997; 38:1054-1059
19. De La Paz MA, Pericak-Vance MA, Lennon F, Haines JL, Seddon JM. Exclusion of TIMP3 as a candidate locus in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1997;38: 1060-1065.
20. Moses M. The regulation of neovascularization by matrix metalloproteinases and their inhibitors. Stem Cells. 1997;15:180-189.
21. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs. 1997;15:61-75.
22. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cherish DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 1998;92:391-400.